Thursday, August 25, 2016
Nymox reports successful new long-term fexapotide placebo crossover study results: major reduction in incidence of surgery.
Results show there was 82-95 pct reduction in number of these patients who required surgery after they received crossover fexapotide in trial.
Has completed and fully financed execution of seven phase 3 U.S. BPH clinical protocols.
Expects to file for approvals in next 1-2 quarters.
Source : reuters.com
